RECPAM: a computer program for recursive partition and amalgamation for censored survival data and other situations frequently occurring in biostatistics. I. Methods and program features-Reference-Cited by-同舟云学术

RECPAM: a computer program for recursive partition and amalgamation for censored survival data and other situations frequently occurring in biostatistics. I. Methods and program features

Published:1988-05 Issue:3 Volume:26 Page:239-256
ISSN:0169-2607
Container-title:Computer Methods and Programs in Biomedicine
language:en
Short-container-title:Computer Methods and Programs in Biomedicine

Author:

Ciampi Antonio,Hogg Sheilah A.,McKinney Steve,Thiffault Johanne

Publisher

Elsevier BV

Subject

Health Informatics,Computer Science Applications,Software

Reference15 articles.

1. Searching for structure: an approach to analysis of substantial bodies of micro-data and documentation for a computer program;Sonquist,1974

2. Classification and regression tress;Breiman,1984

3. Recursive partition: a versatile method for exploratory data analysis in biostatistics;Ciampi,1986

4. A classification of survival experiences of non-Hodgkin's lymphoma patients;Ciampi;Cancer,1981

5. Prognostic factors and risk groups: some results given by using an algorithm suitable for censored survival data;Marubini;Stat. Med.,1983

Cited by 100 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prediction-oriented prognostic biomarker discovery with survival machine learning methods;NAR Genomics and Bioinformatics;2022-06-01

2. Using Weighted Differences in Hazards as Effect Sizes for Survival Data;Journal of Statistical Theory and Practice;2022-02-01

3. A survival tree for interval-censored failure time data;AIMS Mathematics;2022

4. Factors predictive of 90‐day mortality after surgical resection for oral cavity cancer: Development of a recursive partitioning analysis for risk stratification;Head & Neck;2021-05-19

5. The Effects of Time to Treatment Initiation for Patients With Non–small-cell Lung Cancer in the United States;Clinical Lung Cancer;2021-01